Prolactinomas: evolution after menopause
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos de Endocrinologia e Metabolismo (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000100042 |
Resumo: | ABSTRACT Objetive The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. Retrospective study, 29 patients with prolactinomas, 22 microadenomas and 7 macroadenomas, diagnosed during their fertile age were studied in their menopause; treatment was stopped in this period. Age at menopause was 49 ± 3.6 years. The average time of treatment was 135 ± 79 months. The time of follow-up after treatment suspension was 4 to 192 months. Results Pre-treatment PRL levels in micro and macroadenomas were 119 ± 57 ng/mL and 258 ± 225 ng/mL, respectively. During menopause after treatment suspension, and at the latest follow-up: in microadenomas PRL levels were 23 ± 13 ng/mL and 16 ± 5.7 ng/mL, respectively; in macroadenomas, PRL levels were 20 ± 6.6 ng/mL 5t5and 25 ± 18 ng/mL, respectively. In menopause after treatment suspension, the microadenomas had disappeared in 9/22 and had decreased in 13/22. In the group of patients whose tumor had decreased, in the latest follow-up, tumors disappeared in 7/13 and remained unchanged in 6/13. In macroadenomas, after treatment suspension 3/7 had disappeared, 3/7 decreased and 1/7 remained unchanged. In the latest control in the 3 patients whose tumor decreased, disappeared in 1/3, decreased in 1/3 and there was no change in the remaining. Conclusions Normal PRL levels and sustained reduction or disappearance of adenomas were achieved in most of patients, probably due to the decrease of estrogen levels. Dopamine agonists might be stopped after menopause in patients with prolactinomas. |
id |
SBEM-1_40b7b9e457c34c0d9f114c6419337ec4 |
---|---|
oai_identifier_str |
oai:scielo:S2359-39972016000100042 |
network_acronym_str |
SBEM-1 |
network_name_str |
Arquivos de Endocrinologia e Metabolismo (Online) |
repository_id_str |
|
spelling |
Prolactinomas: evolution after menopauseProlactinomamenopausedopamine agonistbromocriptinecabergolineABSTRACT Objetive The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. Retrospective study, 29 patients with prolactinomas, 22 microadenomas and 7 macroadenomas, diagnosed during their fertile age were studied in their menopause; treatment was stopped in this period. Age at menopause was 49 ± 3.6 years. The average time of treatment was 135 ± 79 months. The time of follow-up after treatment suspension was 4 to 192 months. Results Pre-treatment PRL levels in micro and macroadenomas were 119 ± 57 ng/mL and 258 ± 225 ng/mL, respectively. During menopause after treatment suspension, and at the latest follow-up: in microadenomas PRL levels were 23 ± 13 ng/mL and 16 ± 5.7 ng/mL, respectively; in macroadenomas, PRL levels were 20 ± 6.6 ng/mL 5t5and 25 ± 18 ng/mL, respectively. In menopause after treatment suspension, the microadenomas had disappeared in 9/22 and had decreased in 13/22. In the group of patients whose tumor had decreased, in the latest follow-up, tumors disappeared in 7/13 and remained unchanged in 6/13. In macroadenomas, after treatment suspension 3/7 had disappeared, 3/7 decreased and 1/7 remained unchanged. In the latest control in the 3 patients whose tumor decreased, disappeared in 1/3, decreased in 1/3 and there was no change in the remaining. Conclusions Normal PRL levels and sustained reduction or disappearance of adenomas were achieved in most of patients, probably due to the decrease of estrogen levels. Dopamine agonists might be stopped after menopause in patients with prolactinomas.Sociedade Brasileira de Endocrinologia e Metabologia2016-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000100042Archives of Endocrinology and Metabolism v.60 n.1 2016reponame:Arquivos de Endocrinologia e Metabolismo (Online)instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)instacron:SBEM10.1590/2359-3997000000138info:eu-repo/semantics/openAccessMallea-Gil,Maria SusanaManavela,MarcosAlfieri,AnaliaBallarino,Maria CarolinaChervin,AlbertoDanilowicz,KarinaDiez,SabrinaDay,Patricia FainsteinGarcía-Basavilbaso,NataliaGlerean,MarielaGuitelman,MirthaKatz,DéboraLoto,Monica GracielaMartinez,MarcelaMiragaya,KarinaMoncet,DanielRogozinski,Amelia SusanaServidio,MarisaStalldecker,GracielaVitale,MarceloBoero,Lauraeng2016-02-17T00:00:00Zoai:scielo:S2359-39972016000100042Revistahttps://www.aem-sbem.com/https://old.scielo.br/oai/scielo-oai.php||aem.editorial.office@endocrino.org.br2359-42922359-3997opendoar:2016-02-17T00:00Arquivos de Endocrinologia e Metabolismo (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)false |
dc.title.none.fl_str_mv |
Prolactinomas: evolution after menopause |
title |
Prolactinomas: evolution after menopause |
spellingShingle |
Prolactinomas: evolution after menopause Mallea-Gil,Maria Susana Prolactinoma menopause dopamine agonist bromocriptine cabergoline |
title_short |
Prolactinomas: evolution after menopause |
title_full |
Prolactinomas: evolution after menopause |
title_fullStr |
Prolactinomas: evolution after menopause |
title_full_unstemmed |
Prolactinomas: evolution after menopause |
title_sort |
Prolactinomas: evolution after menopause |
author |
Mallea-Gil,Maria Susana |
author_facet |
Mallea-Gil,Maria Susana Manavela,Marcos Alfieri,Analia Ballarino,Maria Carolina Chervin,Alberto Danilowicz,Karina Diez,Sabrina Day,Patricia Fainstein García-Basavilbaso,Natalia Glerean,Mariela Guitelman,Mirtha Katz,Débora Loto,Monica Graciela Martinez,Marcela Miragaya,Karina Moncet,Daniel Rogozinski,Amelia Susana Servidio,Marisa Stalldecker,Graciela Vitale,Marcelo Boero,Laura |
author_role |
author |
author2 |
Manavela,Marcos Alfieri,Analia Ballarino,Maria Carolina Chervin,Alberto Danilowicz,Karina Diez,Sabrina Day,Patricia Fainstein García-Basavilbaso,Natalia Glerean,Mariela Guitelman,Mirtha Katz,Débora Loto,Monica Graciela Martinez,Marcela Miragaya,Karina Moncet,Daniel Rogozinski,Amelia Susana Servidio,Marisa Stalldecker,Graciela Vitale,Marcelo Boero,Laura |
author2_role |
author author author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Mallea-Gil,Maria Susana Manavela,Marcos Alfieri,Analia Ballarino,Maria Carolina Chervin,Alberto Danilowicz,Karina Diez,Sabrina Day,Patricia Fainstein García-Basavilbaso,Natalia Glerean,Mariela Guitelman,Mirtha Katz,Débora Loto,Monica Graciela Martinez,Marcela Miragaya,Karina Moncet,Daniel Rogozinski,Amelia Susana Servidio,Marisa Stalldecker,Graciela Vitale,Marcelo Boero,Laura |
dc.subject.por.fl_str_mv |
Prolactinoma menopause dopamine agonist bromocriptine cabergoline |
topic |
Prolactinoma menopause dopamine agonist bromocriptine cabergoline |
description |
ABSTRACT Objetive The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. Retrospective study, 29 patients with prolactinomas, 22 microadenomas and 7 macroadenomas, diagnosed during their fertile age were studied in their menopause; treatment was stopped in this period. Age at menopause was 49 ± 3.6 years. The average time of treatment was 135 ± 79 months. The time of follow-up after treatment suspension was 4 to 192 months. Results Pre-treatment PRL levels in micro and macroadenomas were 119 ± 57 ng/mL and 258 ± 225 ng/mL, respectively. During menopause after treatment suspension, and at the latest follow-up: in microadenomas PRL levels were 23 ± 13 ng/mL and 16 ± 5.7 ng/mL, respectively; in macroadenomas, PRL levels were 20 ± 6.6 ng/mL 5t5and 25 ± 18 ng/mL, respectively. In menopause after treatment suspension, the microadenomas had disappeared in 9/22 and had decreased in 13/22. In the group of patients whose tumor had decreased, in the latest follow-up, tumors disappeared in 7/13 and remained unchanged in 6/13. In macroadenomas, after treatment suspension 3/7 had disappeared, 3/7 decreased and 1/7 remained unchanged. In the latest control in the 3 patients whose tumor decreased, disappeared in 1/3, decreased in 1/3 and there was no change in the remaining. Conclusions Normal PRL levels and sustained reduction or disappearance of adenomas were achieved in most of patients, probably due to the decrease of estrogen levels. Dopamine agonists might be stopped after menopause in patients with prolactinomas. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-02-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000100042 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972016000100042 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/2359-3997000000138 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
dc.source.none.fl_str_mv |
Archives of Endocrinology and Metabolism v.60 n.1 2016 reponame:Arquivos de Endocrinologia e Metabolismo (Online) instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM |
instname_str |
Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) |
instacron_str |
SBEM |
institution |
SBEM |
reponame_str |
Arquivos de Endocrinologia e Metabolismo (Online) |
collection |
Arquivos de Endocrinologia e Metabolismo (Online) |
repository.name.fl_str_mv |
Arquivos de Endocrinologia e Metabolismo (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) |
repository.mail.fl_str_mv |
||aem.editorial.office@endocrino.org.br |
_version_ |
1752122513880514560 |